Insulet Corporation
Insulet Reports 30% Constant Currency Revenue Growth for 2023
Summary
Insulet Corporation, a leading medical device company, reported a significant 30% constant currency revenue growth for the full year 2023, reaching $1.7 billion. The company saw an impressive 38% constant currency revenue increase in the fourth quarter, with Omnipod revenue contributing significantly to this growth. The company also provided guidance for 2024, expecting revenue growth between 12% and 17% in constant currency. These results reflect Insulet's strong market position and the successful adoption of its Omnipod 5 Automated Insulin Delivery System.
Profitelligence Alerts
Get alerts for PODD
Be first to know when Insulet Corporation files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Insulet Corporation
Insulet Corporation is a prominent healthcare company specializing in medical devices, with a key focus on diabetes management. Its flagship product, the Omnipod Insulin Management System, is an innovative, tubeless insulin pump that offers users freedom and flexibility, addressing the lifelong needs of individuals with diabetes. The system is acclaimed for its discreet, water-resistant pods, which deliver continuous insulin delivery without the constraints of traditional insulin pumps. Insulet Corporation plays a crucial role in the medical technology industry by enhancing patient experiences and outcomes. Headquartered in Acton, Massachusetts, Insulet Corporation continues to pioneer advancements in insulin delivery solutions, directly impacting healthcare providers and improving the quality of life for diabetes patients globally. Its market significance is underscored by its commitment to innovation and accessibility, bridging the gap between technology and patient-centric care in the rapidly evolving healthcare sector.
Official SEC Documents
Advertisement